Danish National Randomized Study on Early Aortic Valve Replacement in Patients With Asymptomatic Severe Aortic Stenosis

NCT ID: NCT03972644

Last Updated: 2020-09-14

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 1700 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-01
• Study Completion Date: 2029-09-01

Brief Summary

The purpose of this study is to examine the impact of early surgery in patients with asymptomatic severe aortic valve stenosis with signs of subclinical LV dysfunction despite preserved LVEF, with a watchfull waiting approach.

Detailed Description

Since the seminal paper by Ross and Braunwald, the development of symptoms has been regarded as one of the most important precursors of a poor outcome in aortic stenosis (AS), and is today half a century later, still the leading reason for referral for aortic valve replacement (AVR). The development of symptoms is however often preceded by structural changes in the left ventricle (LV).These changes including concentric remodeling and LV hypertrophy have been regarded as compensative measures to adapt the LV to increased ventricular afterload. Although LV hypertrophy may preserve wall-stress in the normal range and increase contractility allowing the preservation of stroke volume, this occurs at the expense of increased filling pressures. Diastolic dysfunction with increased filling pressure lead to left atrial (LA) dilatation and significantly contributes to the development of symptoms.

Despite successful surgery, AS patients have increased long-term mortality and morbidity compared to the general population, and the outcome is largely determined by the degree of preoperative structural LV and LA alterations. This has led to the theory that AVR prior to the development of symptoms could improve outcome, a view supported by prospective and retrospective studies.These studies were however small, with some important limitations. In addition, there has been a concern that operative risk and prosthetic valve related long-term morbidity and mortality does not justify surgery on every asymptomatic patient with severe AS. Numerous studies have suggested that markers of LV structure and function, particularly LA volume index,E/e' and brain natriuretic peptides (BNP) all reflecting LV filling pressures may identify patients with benefit of early AVR. Accordingly, the most recent European guideline for management of valvular disease has implemented BNP as a class IIa recommendation for AVR in asymptomatic AS patients,although no randomized studies have demonstrated that early surgery based on these markers improve prognosis.

The purpose of this study is thus to evaluate if early AVR in patients with signs of elevated LV filling pressuresmay improve long-term outcome in patients with asymptomatic severe AS, compared to conventional symptom-guided surgery.

Conditions

Aortic Valve Stenosis; Diastolic Dysfunction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Early intervention

Patients will undergo aortic valve replacement immediately

Group Type: ACTIVE_COMPARATOR

Aortic valve replacement

Intervention Type: PROCEDURE

Open heart surgery or transcatheter surgery

Watchfull waiting

Patients will be followed and treated as recommended by guidelines.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Aortic valve replacement

Open heart surgery or transcatheter surgery

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• 1. Severe AS defined as

1. aortic valve area (AVA) ≤1 cm2, AND

2. Transvalvular maximum velocity (Vmax) ≥3.5 m/s AND

3. AS severity evaluated severe by a heart valve team conference. In cases where severity is not unambiguous an integrative approach will be utilized combining echocardiographic markers of valve severity and LV function, and if necessary aortic valve calcification estimated by non-contrast CT.

2. Considered to be asymptomatic (estimated by a consultant in cardiology) 3. Considered to be candidate for AVR (transcatheter AVR/surgical AVR) 4. Sign of increased LV filling pressures18 or reduced longitudinal LV systolic function

<!-- -->

1. Left atrial volume index (LAVi) > 34 ml/m2; OR

2. ratio of early diastolic peak mitral inflow velocity (E) to early mitral annulus diastolic velocity (e') ratio E/e'avg>13; OR

3. Threefold elevation in NT-proBNP compared to the upper expected age and gender value. OR

4. GLS>-15 5. Age ≥18 years 6. Signed informed consent

Exclusion Criteria

1. LVEF<50%

2. Very severe AS defined as Vmax>5 m/s.

3. Concomitant severe valvular disease other than AS

4. Previous valvular surgery

5. Estimated glomerular filtration rate<30 ml/min/m2

6. Dementia

7. Women of childbearing potential

8. Inability to provide informed consent

9. Age>85 years.

10. Supravalvular or subvalvular AS

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rigshospitalet, Denmark

OTHER

Sponsor Role: collaborator

Aarhus University Hospital

OTHER

Sponsor Role: collaborator

Aalborg University Hospital

OTHER

Sponsor Role: collaborator

Zealand University Hospital

OTHER

Sponsor Role: collaborator

Odense University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Jordi Dahl

Associate Professor, MD, Ph.D.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Odense University Hospital

Odense, Fyn, Denmark

Site Status: RECRUITING

Countries

Denmark

Central Contacts

Jordi S Dahl, MD, PhD

Role: CONTACT

jordi.dahl@rsyd.dk

+4523823016

Jacob E Møller, MD, PhD

Role: CONTACT

jem@dadlnet.dk

Facility Contacts

Jordi S Dahl, MD, Ph.D

Role: primary

jordi.dahl@rsyd.dk

23823016

Other Identifiers

S-20190006

Identifier Type: -

Identifier Source: org_study_id